dQ&A's latest diabetes research includes two presentations from our team at ATTD 2026, one of the world's leading stages for diabetes advancements.
This survey shows COVID-19 booster rates are higher in U.S. adults with diabetes than the general population, but vary by race, income, and location.
We surveyed panel members about the FDA advisory on Provention Bio’s teplizumab to delay type 1 diabetes—discover their top concerns and expected impact.
This research reveals how stigma in diabetes—from HCPs and society—affects relationships, care decisions, mental health, and diabetes management.
ADA and dQ&A survey results reveal that COVID fears kept one in five people with diabetes away from the doctor during the pandemic.
Which diabetes groups lead or lag on COVID-19 shots? See dQ&A’s panel results from March 2021 and uncover barriers to higher coverage.
Our survey finds major pharmacies often fail people with diabetes, with wide NPS score gaps; Sam’s Club, Publix, Costco, and U.S. Medical Supply rank highest.
5,700 dQ&A community members share where they were diagnosed, first symptoms, and emotions—highlighting key differences between type 1 and type 2 journeys.
This study examines how income affects diabetes outcomes, finding lower-income adults with type 2 diabetes face higher rates of complications and depression.
